Profil
Colin Hayward worked as Vice President-Medical Affairs at Premier Research Group Ltd. from 2013 to 2014.
Prior to that, he was a Principal at Roche Products Ltd. from 2001 to 2001 and Executive Vice President at Prism Ideas Ltd. from 2007 to 2011.
Currently, he is serving as Chief Medical Officer at Telix Pharmaceuticals Ltd. from 2020 to 2024.
Dr. Hayward holds a doctorate degree from the University of London.
Ehemalige bekannte Positionen von Colin Hayward
| Unternehmen | Position | Ende |
|---|---|---|
| TELIX PHARMACEUTICALS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2024 |
Premier Research Group Ltd.
Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2014 |
Prism Ideas Ltd. | Corporate Officer/Principal | 01.12.2011 |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Manufactures diagnostic, diabetes and pharmaceutical products | Corporate Officer/Principal | 01.03.2001 |
Ausbildung von Colin Hayward
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Premier Research Group Ltd.
Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Commercial Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Manufactures diagnostic, diabetes and pharmaceutical products | Health Technology |
Prism Ideas Ltd. | |
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. BiotechnologyHealth Technology Operates as a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals | Health Technology |
















